Prevention, screening and therapy of thyroid diseases and their cost-effectiveness;Prävention, Screening und Therapie gutartiger Schilddrü senerkrankungen unter dem Aspekt von Kosten und Nutzen

NuklearMedizin

Volumn 42, Issue 5, 2003, Pages 181-189

  Dietlein, M ^a   Moka, D ^b   Schmidt, M ^b   Theissen, P ^b   Schicha, H ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

Cost benefit; Cost effectiveness; Prevention; Screening; Thyroid diseases

Indexed keywords

ANTITHYROID AGENT; CALCITONIN; CALCIUM; IODINE; RADIOACTIVE IODINE; THYROTROPIN;

COMORBIDITY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DATA BASE; DEATH; ECHOGRAPHY; FOLLOW UP; GRAVES DISEASE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTHYROIDISM; LIFE EXPECTANCY; NODULAR GOITER; PRIMARY PREVENTION; QUALITY ADJUSTED LIFE YEAR; RELAPSE; REVIEW; SCREENING; SECONDARY PREVENTION; SMOKING; THYROID DISEASE; THYROTROPIN BLOOD LEVEL;

EID: 0142260533     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625188     Document Type: Review

References (87)

1. Allahabadia A, Daykin J, Holder RL et al. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab 2000; 85: 1038-42.
2. Bartalena L, Marcocci C, Bogazzi F et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998; 338: 73-8.
3. Bleichrodt N, Born MP. A metaanalysis of research on iodine and its relationship to cognitive development. In: Stanbury JB (ed). The damaged brain of iodine deficiency. Cognizant Communication, New York, 1994,195-200.
4. Bonds DE, Freedberg KA. Cost-effectiveness of prenatal screening for postpartum thyreoiditis. J Womens Health Gend Based Med 2001; 10: 649-58.
5. Bonnema SJ, Bartalena L, Toft AD et al. Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. Eur J Endocrinol 2002; 147: 1-11.
6. Bonnema SJ, Bertelsen H, Mortensen J et al. The feasibility of high dose iodine-131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab 1999; 84: 3636-41.
7. Castro MR, Caraballo J, Morris JC. Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis. J Clin Endocrinol Metab 2002; 87:4145-59.
8. Cooper DS, Ridgway EC. Thoughts on prevention of thyroid disease in the United States. Thyroid 2002; 12: 925-9.
9. Danese MD, Powe NR, Sawin CT et al. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. JAMA 1996; 276: 285-92.
10. Dederichs B, Otte R, Klink JE et al. Volumen-reduktion der Schilddrüse nach Radioiodtherapie bei Patienten mit Schilddrü senautonomie und Morbus Basedow. Nuklearmedizin 1996; 35:164-9.
11. Delange F, Bürgi H, Pei Chem Z et al. World status of monitoring of iodine deficiency disorders control programs. Thyroid 2002; 12: 915-24.
12. Denizot A, Dadoun F, Meyer-Dutour A et al. Screening for primary hyperparathyreoidism before thyroid surgery: a prospective study. Surgery 2002; 131:264-9.
13. Derwahl M, Broecker M, Kraiem Z. Clinical review 101: Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors. J Clin Endocrinol Metab 1999; 84: 829-34.
14. Dietlein M, Dederichs B, Weigand A et al. Radioiodine therapy and Graves' ophthalmopathy: risk factors and preventing effects of glucocorticoids. Exp Clin Endocrinol Diabetes 1999; 107 (Suppl 5): S190-4.
15. Dietlein M, Dressler J, Eschner W et al. Procedure guideline for radioiodine test (version 2). Nuklearmedizin 2003; 42: 116-9.
16. Dietlein M, Dressler J, Eschner W et al. Procedure guideline for thyroid scintigraphy (version 2). Nuklearmedizin 2003; 42:120-2.
17. Dietlein M, Dressler J, Grünwald F et al. Guideline for in vivo- and in vitro procedures for thyroid diseases (version 2) Nuklearmedizin 2003; 42: 109-15.
18. Dietlein M, Dressler J, Joseph K et al. Leitlinie zur Radioiodtherapie (RIT) bei benignen Schilddrüsenerkrankungen (Version 2). Nuklearmedizin 2002; 41: N72-3.
19. Dietlein M, Geckle L, Overbeck T et al. Kostenminimierungsstudie zur definitiven Therapie der Hyperthyreose: Vergleich zwischen Strumaresektion und Radioiodtherapie. Nuklearmedizin 1997; 36: 150-6.
20. Dietlein M, Moka D, Hunsche E et al. KostenEffektivitäts-Analyse: Radioiod oder thyreostatische Medikation bei der Primärbehandlung der Immunhyperthyreose. Nuklearmedizin 1999; 38: 7-14.
21. Dietlein M, Schicha H. PET in der nuklearmedizinischen Diagnostik - Kosten/Nutzen-Aspekte. Nuklearmedizin 2002; 41: 202-7.
22. Dietlein M, Schicha H. Lifetime follow-up care is necessary for all patients with treated thyroid nodules. Eur J Endocrinol 2003; 148: 377-9.
23. Dietlein M, Troche CJ, Moka D et al. Auswirkungen der neuen Entlassungsrichtwerte auf die Kostenstruktur der Radioiodtherapie. Nuklearmedizin 1998; 37: 26-33.
24. Glinoer D, Hesch D, Lagasse R et al. The management of hyperthyroidism due to Graves' disease in Europe in 1986. Results of an international survey. Acta Endocrinol (Suppl) 1987; 185: 9-37.
25. Glinoer D, de Nayer P, Bex M, the Belgian Collaborative Study Group on Graves' Disease. Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomised study. Eur J Endocrinol 2001; 144:475-83.
26. Gow SM, Elder A, Caldwell G et al. An improved approach to thyroid function testing in patients with non-thyroidal illness. Clin Chim Acta 1986; 158: 49-58.
27. Haddow JE, Palomaki GE, Allan WC et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med 1999; 341: 549-55.
28. 131I incorporation in nuclear medicine personnel by self accomplished measurements. Nuklearmedizin 2003; 42: 45-8.
29. Hak E, Pols HAP, Visser TJ et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam Study. Ann Intern Med 2000; 132: 270-8.
30. Hardisty CA, Jones SJ, Hedley AJ et al. Clinical outcome and cost of care in radioiodine treatment of hyperthyroidism. J Royal Coll Phys London 1990; 24: 36-42.
31. Huysmans DA, Hermus AR, Corstens FH et al. Large compressive goiters treated with radioiodine. Ann Intern Med 1994; 121: 757-62.
32. Kahaly GJ, Dietlein M. Cost estimation of thyroid disorders in Germany. Thyroid 2002; 12: 909-14.
33. Kaplan MM, Reed Larsen P, Cranzt FR et al. Prevalence of abnormal thyroid function test results in patients with acute medical illnesses. Am J Med 1982; 72:9-16.
34. Khandani A, Schicha H. Zweizeitige Radioiodtherapie benigner Schilddrüsenerkrankungen während eines stationären Aufenthaltes - Beobachtungen an 100 Patienten. Nuklearmedizin 1999; 38: 140-3.
35. de Klerk JM, van Isselt JW, van Dijk A et al. Iodine-131 therapy in sporadic nontoxic goiter. J Nucl Med 1997; 38: 372-6.
36. Knudsen N, Laurberg P, Perrild H et al. Risk factors for goiter and thyroid nodules. Thyroid 2002; 12: 879-88.
37. Lauterbach KW. Schrappe M. Gesundheit-ökonomie, Qualitä tsmanagement und Evidence-based Medicine - Eine systematische Einführung. Stuttgart: Schattauer 2001.
38. Lazarus JH. Epidemiology and prevention of thyroid disease in pregnancy. Thyroid 2002; 12: 861-5.
39. Ljunggren JG, Törring O, Wallin G et al. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 1998: 8: 653-9.
40. Meier C, Staub J-J, Roth C-B et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double-blind placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 2001; 86: 4860-6.
41. Michelangeli V, Poon C, Taft J et al. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 1998; 8: 119-24.
42. Moka D, Dietlein M, Schicha H. Radioiodine therapy and thyrostatic drugs and iodine. Eur J Nucl Med 2002; 29 (Suppl 2): S486-91.
43. Moka D, Schicha H, Körber C et al. Zum Editorial: Reduzieren Thyreostatika die Erfolgsrate in der Radioiodtherapie? Nuklearmedizin 2000: 39: N25.
44. Moka D, Voth E, Schicha H. Einfluss von thyreostatischer Medikation auf die effektive Halbwertszeit und den Uptake von Iod-131 während einer Radioiodtherapie. Nuklearmedizin 1997; 36: 87-92.
45. Moser E. Radioiodtherapie bei Morbus Basedow - Gibt es einen therapeutischen Standard? Zbl Chir 1997; 122: 227-30.
46. Nedrebo BG, Holm PI, Uhlving S et al. Predictors of outcome and comparison of different drug regimes for the prevention of relapse in patients with Graves' disease. Eur J Endocrinol 2002; 147: 585-9.
47. Orgiazzi J, Madec A-M. Reduction of the risk of relapse after withdrawal of medical therapy for Graves' disease. Thyroid 2002; 12: 849-53.
48. Pacini F, Fontanelli M, Fugazzola L et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994; 78: 826-9.
49. Parle JV, Maisonneuve P, Sheppard MC et al. Prediction of all-cause and cardiovascular mortality in elderly people frorn one low serum thyrotropin result: a 10-year cohort study. Lancet 2001; 358: 861-5.
50. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current versus lifetime cigarette consumption. Clin Endocrinol (Oxf) 1996; 45: 477-81.
51. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA 1993; 269: 479-82.
52. Quadbeck B, Pruellage J, Roggenbuck U et al. Long-term follow-up of thyroid nodule growth. Exp Clin Endocrinol Diabetes 2002; 110: 348-54.
53. Reiners Chr, Schicha H. StrlSchV 2001 und »Richtlinie Strahlenschutz in der Medizin«: Konsequenzen für die Nuklearmedizin. Nuklearmedizin 2002; 41: 168-70.
54. Richtlinie Strahlenschutz in der Medizin vom 24. Juni 2002. Bundesanzeiger 54 (Nummer 207a), ausgegeben am 7. November 2002, Bonn 2002.
55. Riemann B, Schober O. Cross Section Nuclear-Medicine. Nuklearmedizin 2002; 41: 1-2.
56. Rieu M, Lame C-C, Richard A et al. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol 1995; 42: 453-60.
57. Sabri O, Zimny M, Schreckenberger M et al. Characterisation of radioiodine therapy failures in Graves' disease. Nuklearmedizin 2001; 40:1-6.
58. Sabri O, Zimny M, Schulz G et al. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab 1999; 84:1229-33.
59. Sawin CT, Geller A, Wolf PA et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331: 1249-52.
60. Scheidhauer K, Odatzidu L, Kiencke P et al. Body weight gain after radioiodine therapy of hyperthyroidism. Nuklearmedizin 2002; 41: 47-51.
61. Schicha H. Muss die hohe Hypothyreosegabe nach Radioiodtherapie einer immunogenen Hyperthyreose in Kauf genommen werden? Nuklearmedizin 1997; 36: 6.
62. Schicha H, Dietlein M. Morbus Basedow und Autonomie - Radioiodtherapie. Nuklearmedizin 2002; 41: 63-70.
63. Schneider P, Körber C, Körber-Hafner N et al. Does an individual estimation of halflife improve the results of radioiodine therapy of Graves' disease? Nuklearmedizin 2002; 41: 240-4.
64. Schomäcker K, Fischer T, Eschner W et al. Exhalation of 1-131 after radioiodine therapy: time dependence and chemical form. Nuklearmedizin 2001; 40:15-22.
65. Small M, Buchanan L, Evans R. Value of screening thyroid function in acute medical admissions to hospitals. Clin Endocrinol 1990; 32: 185-91.
66. Solomon B, Glinoer D, Lagasse et al. Current trends in the management of Graves' disease. J Clin Endocrinol Metab 1990; 70: 1518-24.
67. Spitzenverbände der Krankenkassen, Verband der privaten Krankenversicherung, Deutsche Krankenhausgesellschaft. Fallpauschalenkatalog vom 25. September 2002. www.g-drg.de.
68. Strahlenschutzkommission (SSK): Ambulante, fraktionierte Radioiodtherapie. Empfehlung der Strahlenschutzkommission. Bundesanzeiger Nr. 123 vom 18. Juli 1996, Bonn (S. 8117).
69. Statistisches Bundesamt Deutschland 2002. Gesundheitswesen. www.destatis.de.
70. Strahlenschutzverordnung vom 20. Juni 2001, geändert vom 18. Juli 2002; Textausgabe mit Anmerkungen von Witt E, Jäger E, Kaspar L. Köln: Carl Heymanns 2002.
71. Tengs TO, Adams ME, Pliskin JS et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15: 369-90.
72. Theissen P, Lind T, Jockenhövel F et al. Häufigkeit von Schilddrüsenfehlfunktionen bei steigender Iodversorgung. Nuklearmedizin 2003; 42: A11.
73. Urbannek V, Schmidt M, Moka D et al. Influence of iodine application during radioiodine therapy in case of impending therapy failure. Nuklearmedizin 2000; 39:108-12.
74. Urbannek V, Voth E, Moka D et al. Radioiodtherapie des Morbus Basedow - dosimetrischer Vergleich verschiedener Therapieregime bezüglich der Thyreostatikagabe. Nuklearmedizin 2001; 40: 111-5.
75. Vanderpump MPJ, Tunbridge MG. Epidemiology and prevention of clinical and subclinical hypothyroidism. Thyroid 2002; 12: 839-47.
76. Vanderpump MPJ, Tunbridge WMG, French JM et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Wickham Survey. Clin Endocrinol 1995; 43: 55-69.
77. Vidal-Trecan GM, Stahl JE, Durand-Zaleski I. Managing toxic thyroid adenoma: a cost-effectiveness analysis. Eur J Endocrinol 2002; 146: 283-94.
78. Vielhapper H, Raber W, Bieglmayer C et al. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 1997; 82: 1589-93.
79. Vitti P, Rago T, Chiovato L et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997; 7: 369-75.
80. Walsh JP. Management of Graves' disease in Australia. Aust NZ J Med 2000; 30:559-66.
81. Wartofsky L, Glinoer D, Solomon B et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1991; 1: 129-35.
82. Weber K, Wellner U, Voth E et al. Influence of stable iodine on the uptake of the thyroid model vs. experiment. Nuklearmedizin 2001; 40:31-7.
83. Weigand A, Hinzpeter B, Schicha H. Verschlechterung einer endokrinen Orbitopathie nach Radioiodtherapie bei M. Basedow? Nuklearmedizin 1998; 37: 234-8.
84. Wesche MFT, Tiel-v Buul MMC, Lips P et al. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic non-toxic goiter. J Clin Endocrinol Metab 2001; 86: 998-1005.
85. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 2002; 12: 855-60.
86. Zelmanovitz F, Genro S, Gross JL. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab 1998; 83: 3881-5.
87. Zöphel K, Wunderlich G, Kopprasch C et al. Predictive value of thyrotropin receptor antibodies using the second generation TRAb human assay after radioiodine treatment in Graves' disease. Nuklearmedizin 2003; 42: 63-70.